You're contacting media contact of this press release

Title: CoreAge Rx Introduces NAD+ Injectable Therapy to Support Cellular Energy, Cognitive Function, and Healthy Aging

Wichita Falls, TX, United States, 24th Apr 2026 - CoreAge Rx, a LegitScript-certified telehealth provider specializing in medically supervised weight management and wellness protocols, has announced the launch of its NAD+ (Nicotinamide Adenine Dinucleotide) Injectable, a new addition to its growing portfolio of therapies focused on cellular health, energy metabolism, and longevity support.The NAD+ Injectable is introduced as part of CoreAge Rx’s broader “Brain + Body Energy Protocol,” offering patients a structured, physician-guided approach to supporting mitochondrial function, cognitive clarity, and metabolic efficiency. The therapy is administered via intramuscular or subcutaneous injection and is available through the company’s fully digital care platform.Addressing Declining NAD+ Levels with Targeted DeliveryNAD+ is a coenzyme found in every cell of the body and plays a central role in energy production, DNA repair, and cellular maintenance. As individuals age, NAD+ levels naturally decline, which has been associated with reduced energy, cognitive changes, and metabolic inefficiencies.CoreAge Rx’s injectable NAD+ formulation is designed to deliver the compound directly into the bloodstream, allowing for rapid absorption and systemic distribution. This delivery method is intended to support both neurological and physiological processes more efficiently compared to traditional oral supplementation.By integrating NAD+ therapy into its telehealth model, CoreAge Rx enables patients to access physician-reviewed protocols without the need for in-person visits, while maintaining structured medical oversight throughout the process.Key Features and Potential BenefitsAccording to CoreAge Rx, the NAD+ Injectable is formulated to support a range of wellness goals, including:Inc...

This press release is issued by King Newswire